Eton Pharmaceuticals (ETON) announced that it has launched Galzin capsules. Galzin is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent. It is the only FDA-approved zinc therapy for Wilson disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals granted new patent from USPTO
- Eton Pharmaceuticals: Buy Rating Backed by Upcoming Catalysts and Market Opportunities
- Eton Pharmaceuticals: FDA extends PDUFA date for NDA for ET-400 to 5/28
- Eton Pharmaceuticals price target raised to $23 from $18 at Craig-Hallum
- Eton Pharmaceuticals price target raised to $33 from $17 at H.C. Wainwright